Acrivon Therapeutics (ACRV) Other financing activities (2023 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Other financing activities of $1000.0 for Q1 2025, down 98.73% year-over-year from $79000.0 in Q1 2024, and down 100.0% quarter-over-quarter from $69.9 million in Q4 2024.
Acrivon Therapeutics (ACRV) Other financing activities (2023 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Other financing activities for 3 consecutive years, with $1000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Other financing activities fell 98.73% year-over-year to $1000.0; the TTM figure through Dec 2025 stood at $1000.0 (down 100.0% YoY), while the FY2025 annual figure was $1000.0, down 100.0% from the prior year.
- Other financing activities slipped to $1000.0 in Q1 2025 per ACRV's latest filing, from $69.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $69.9 million in Q4 2024 and bottomed at $1000.0 in Q1 2025.
- Historically, Other financing activities has averaged $11.7 million across 3 years, with a median of $78500.0 in 2023.
- Annual changes were most pronounced in 2024 — Other financing activities jumped 21883.33% — and 2025, when it tumbled 98.73%.
- Acrivon Therapeutics' Other financing activities stood at $318000.0 in 2023, then surged by 21883.33% to $69.9 million in 2024, then plunged by 100.0% to $1000.0 in 2025.
- Business Quant data shows ACRV's Other financing activities at $1000.0 in Q1 2025, $69.9 million in Q4 2024, and $11000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8,000.00 |
| Jun 30, 2026 | 8,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 69.91 Mn |
| Dec 31, 2024 | 69.91 Mn |
| Jun 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 318,000.00 |
| Dec 31, 2023 | 318,000.00 |
| Sep 30, 2023 | 78,000.00 |
| Sep 30, 2023 | 78,000.00 |